Claims for Patent: 8,591,885

Summary for Patent: 8,591,885

Title:	Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
Abstract:	Biocompatible intraocular drug delivery systems include a carbonic anhydrase inhibitor therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.
Inventor(s):	Chang; James N. (Newport Beach, CA), Hughes; Patrick M. (Aliso Viejo, CA), Devries; Gerald W. (San Clemente, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	11/931,769
Patent Claims:	1. A sustained release intraocular drug delivery system comprising: a first therapeutic component selected from the group consisting of acetazolamide, brinzolamide, dorzolamide, and methazolamide, a second therapeutic component selected from ranibizumab and bevacizumab, and a polymeric component comprising hyaluronic acid; wherein said system is formulated to release at least 10% of its active ingredient in the first two weeks following administration to the posterior chamber of a human eye. 2. The system of claim 1 wherein said system is formulated to release at least 20% of its active ingredient in the first two weeks following administration to the posterior chamber of a human eye. 3. The system of claim 1 wherein said system is formulated to release at least 30% of its active ingredient in the first two weeks following administration to the posterior chamber of a human eye. 4. The system of claim 1 wherein said system is formulated to release at least 40% of its active ingredient in the first two weeks following administration to the posterior chamber of a human eye. 5. The system of claim 1 in which said first therapeutic component is present in a viscous aqueous medium.

Details for Patent 8,591,885

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2024-04-30
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2024-04-30
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2024-04-30
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2024-04-30
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018		2024-04-30